Sarepta Therapeutics (SRPT) PT Lowered at Piper Sandler After a 'Voluntary Pause Of Elevidys'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Citi Opens 90d Downside Catalyst Watch on Sarepta Therapeutics (SRPT)
July 24, 2025 6:46 AM EDTCiti Opens 90d Downside Catalyst Watch on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "We are opening a 90-day downside short-term view on SRPT. Our view is anchored on new and open questions surrounding Elevidys marketing approval in ambulatory Duchenne patients, the possibility of... More
